… Furthermore, working with closed systems can optimize and facilitate the production of
Advanced Therapy Medical Products in GMP environments, by providing an easily reproducible …

… It prepares HTA reports either at G-BA requests or self-initialized (for non-pharmaceutical
products) [40]. It does not have any decision-making powers and its advice to the G-BA (eg …

… of carer burden in health technology assessments (HTA) in … of carer burden could
impact gender health inequality. … retrieved from value dossiers of 17 medicinal products (n=46 …

… specificities of the products which are always developing, eg with the introduction of
different advanced therapy medicinal products (ATMPs) including gene therapies [Citation66–…

… GTs have challenged their evaluations in health technology assessment (HTA); hence…
Advanced therapy medicinal products and health technology assessment principles and practices …

… entry of new pharmaceutical products and mitigate risks related to premature evidence (7;8);
one way to achieve this has been through the introduction of contractual arrangements …

… Advanced therapy medicinal products are complex in nature, with risks varying
depending on the product type, characteristics of starting materials, and the complexity of the …

… on how best to use InMPs and communicate the value of products to external stakeholders,
including Health Technology Assessment bodies. In addition, insights from post-approval …

… -wide added value or research priorities; and breakthrough technology for oncology products
and/or advanced therapy medicinal products (34). The criteria ensured that the resources …

… of biotechnological techniques have led to the development of innovative therapies known
as advanced therapy medicinal products (ATMPs), which are a class of biological products for …